Selected article for: "anti SARS cov and clinical evidence"
Author: Zou, Li; Dai, Lijun; Zhang, Xingyu; Zhang, Zhaohui; Zhang, Zhentao
Title: Hydroxychloroquine and chloroquine: a potential and controversial treatment for COVID-19
  • Cord-id: i4r71gj7
  • Document date: 2020_8_1
    • ID: i4r71gj7
    Snippet: A novel coronavirus, later named SARS-CoV-2, was first reported in China in December 2019 and subsequently widely identified in the United States, Japan, South Korea, France, India, and other countries. The disease caused by SARS-CoV-2 infection was called COVID-19. The high fatality and morbidity rates of COVID-19 make it the third largest global epidemic in this century. However, there are currently no approved antiviral drugs for the COVID-19 treatment. Recently, two old antimalarial drugs, h
    Document: A novel coronavirus, later named SARS-CoV-2, was first reported in China in December 2019 and subsequently widely identified in the United States, Japan, South Korea, France, India, and other countries. The disease caused by SARS-CoV-2 infection was called COVID-19. The high fatality and morbidity rates of COVID-19 make it the third largest global epidemic in this century. However, there are currently no approved antiviral drugs for the COVID-19 treatment. Recently, two old antimalarial drugs, hydroxychloroquine and chloroquine, have been found to exert anti-SARS-CoV-2 effects both in vitro and in vivo. Preliminary clinical evidence suggests these drugs may have an effect on the treatment of COVID-19. Herein, we review the pharmacokinetics characteristics and antiviral effects of these drugs, in addition to their side effects and clinical evidence of their use for the COVID-19 treatment.

    Search related documents:
    Co phrase search for related documents
    • acute ards respiratory distress syndrome and liver renal: 1, 2, 3, 4, 5, 6, 7, 8
    • acute ards respiratory distress syndrome and liver renal disease: 1
    • acute ards respiratory distress syndrome and long period: 1, 2
    • acute ards respiratory distress syndrome and long term effect: 1
    • acute ards respiratory distress syndrome and lung kidney: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
    • acute ards respiratory distress syndrome and lupus patient: 1
    • liver renal and lung kidney: 1, 2, 3
    • liver renal disease and lung kidney: 1
    • long period and lung kidney: 1, 2